Predictive markers for egfr inhibitors treatment

An in vitro method of predicting the response of a cancer patient to treatment with an epidermal growth factor receptor (EGFR) inhibitor comprising:

• Determining the expression level of at least one gene selected from the group consisting of glioblastoma amplified sequence (GBAS), apolipoprotein H (APOH), SCY1-like 3 (SCYL3), PMS2CL, PRODH, SERF1A, URG4A and LRRC31 in a tumour sample of a cancer patient and comparing the expression level of the at least one gene in the tumour sample to a value representative of an expression level of the at least one gene in a non responding patient population, wherein a higher expression level of the at least one gene in the tumour sample of the patient is indicative for a patient who will respond to the treatment.